Kornimate/medical-research-clean huggingface dataset:
evaluation of the benefit provided by acupuncture during a surgery of deep brain stimulation

Conditions: Parkinson's Disease

Summary: the effectiveness of deep brain stimulation (dbs) in certain movement disorders is widely demonstrated. the success of this procedure requires that the patient is awake and cooperative. the conditions of this intervention can be difficult to tolerate by the patient for several reasons: long procedure (from 3 to 8 hours), body immobilisation (particularly the head in the stereotactic frame), stress related to the localization of the dbs. it is therefore important to improve the comfort as well as the cooperation of the patient, during implantation of the dbs electrodes, in order to optimize the conditions of the intervention. in addition to analgesia, acupuncture should allow sedation without affecting alertness and should contribute to the regulation of any vegetative reactions during the procedure. therefore, we hypothesize that acupuncture could improve the quality of care of the patient during a dbs procedure. in practice, this is electroacupuncture that will be used in this research to maintain the stimulation of acupuncture points to an optimal level during the time of the intervention.


Eligibility criteria:
inclusion criteria: * patients from both sexes aged who are \>= 18 years * disabling movement disorders, resistant to medical treatment, in parkinson's patients who should benefit from a deep brain stimulation in the subthalamic nucleus * scheduled intervention of a deep brain stimulation * understanding of acupunctural analgesia with electrostimulation * signed informed consent * membership to a social security insurance scheme exclusion criteria: * patients who are \>= 75 years * history of intolerance to acupuncture * contraindications to local anesthesia * respiratory problems (asthma, copd, ...) * holder of an implanted pacemaker * obesity with bmi \> 30 * history of motion sickness * unstabilized psychiatric disorders * impaired cognitive functions * pregnancy * breastfeeding * minors * major under a legal protection regime
effect of intensive cognitive rehabilitation in subacute stroke patient

Conditions: Stroke; Rehabilitation; Cognitive Function

Summary: early stroke rehabilitation is known to be an effective and essential therapy in gaining functional independence and preventing complications. however, there was no consensus of proper amount of cognitive rehabilitation in stroke patients. in this study, the investigators assess the effects of the intensive cognitive rehabilitation during subacute phase to improve cognitive function at 6 months after onset in patients with first-ever strokes.

intensive cognitive rehabilitation group * cognitive therapy for 1 hours on every working day for 4 weeks conventional cognitive rehabilitation group * cognitive therapy for 30 minutes on every working day for 4 weeks

Eligibility criteria:
inclusion criteria: * acute first-ever stroke * korean mini-mental state examination: 11\~24 at 7 days after stroke onset exclusion criteria: * transient ischemic stroke
powersforid: a telehealth weight management system for adults with intellectual disability

Conditions: Intellectual Disability; Weight Loss; Motivational Interviewing; Telehealth

Summary: powersforid is a 24 week randomized control trial designed to assess the feasibility of a telehealth and coaching intervention for improving health outcomes of adults with intellectual disability. recruitment is conducted through a disability health clinic located in colorado springs, co.

powers (personalized online weight and exercise response system) platform is a novel, multifocal-centered tailored intervention utilizing an innovative online tool designed to facilitate improvements in physical activity and nutritional behaviors. aim 1 of this protocol is to customize the powers platform, demonstrated effective in previous research, for adults with intellectual disability (id) and their caregivers to be referred to as powersforid. the powersforid intervention is designed to achieve weight loss and improve specific health markers while respecting and supporting the needs of the participants with id as well as their caregivers. aim 2 of the project is to conduct a pilot study to assess the usability and feasibility of the powersforid system and intervention with 5 adults with id and their caregiver and improve the system based on pilot data. aim 3 of the protocol is to conduct a randomized controlled trial (rct) to examine the effect of powersforid on educating and coaching caregivers about nutrition and exercise and thus improving health status and reducing body weight in obese adults with id. the investigators hypothesize that the obese participants in the intervention group (powersforid) will evidence significantly greater weight loss and improved health status (i.e. lower waist circumference, blood pressure, decreased body fat percentage, and improved blood lipids) compared to a control group. the investigators also hypothesize that both adults with id and their caregivers will demonstrate improved knowledge, attitudes, and self-efficacy related to diet and exercise.

Eligibility criteria:
inclusion criteria: * participants with intellectual disability (id) who meet the following inclusion criteria are eligible to participate in the study: * body mass index \> or equal to 30 kg/m2; * diagnosis of mild or moderate id; * 25 to 50 years of age; * medical provider approval to participate in a weight loss program; * has a caregiver who agrees to participate in the study and provides services 4 days a week or more to the adult with id; * has access to a computer with internet throughout the week. exclusion criteria: * currently on a weight loss program; * medical conditions that prevent participation as noted by the medical provider or legal guardian including heart and/or renal disease; * behavioral issues determined by the ddhc behavioral health staff; * unable to walk or exercise due to a mobility impairment or medical condition; * judged to have insufficient capacity to consent or assent as assessed using the "supplemental consent document".
serum concentration of adalimumab as a predictive factor of clinical outcomes in rheumatoid arthritis (afora)

Conditions: Rheumatoid Arthritis

Summary: adalimumab is a fully human monoclonal antibody to tumor necrosis factor-alpha (tnf-α) approved in rheumatoid arthritis (ra) refractory to disease modifying anti rheumatic drugs (dmards) and for the treatment of severe, active and progressive ra in adults not previously treated with methotrexate. however, almost one third of patients have no response and approximately 15% develop antibodies towards adalimumab (ata) after a 6 month course of treatment. there is a relationship between adalimumab concentration and clinical response obtained after 6 month of treatment. furthermore adalimumab concentration measured 3 months after initiation seems to predict the clinical response at 6 months. there is an important inter individual pharmacokinetic variability of adalimumab. side effects may occur at the recommended dose and more than 3 months of treatment are generally required to estimate the clinical response. a therapeutic drug monitoring could help clinicians to early adjust the dose to optimize the response and to avoid dose related side effects. to date there is no definite adalimumab target concentration predictive of the clinical response to allow such a pharmacologic monitoring.


Eligibility criteria:
inclusion criteria: * ra according to the american college of rheumatology (acr) 1987 criteria * treatment with adalimumab has been chosen by the physician / patient * treatment given in accordance to the spc * stable disease modifying anti rheumatic drugs (dmards) and glucocorticoids 4 weeks before enrollment and during the study period. * signed consent exclusion criteria: * more than one previous treatment with anti tnf-alpha * past history of malignancy, aids * pregnancy * change in dmards or glucocorticoid dose 4 weeks before entering the study * active or latent tuberculosis, other active infections * surgery scheduled during the study period

Keywords: rheumatoid arthritis adalimumab pharmacokinetic-pharmacodynamic relationship immunogenicity fc gamma receptors polymorphisms
effect of strain counter strain technique in treatment of lower back myofascial pain syndrome

Conditions: Lower Back Myofascial Pain Syndrome

Summary: this study aims to investigate the impact of impact of strain counterstrain technique on pain, lumbar range of motion and functional impairment in patients with lower back myofascial pain syndrome.

myofascial pain syndrome (mps) is a prevalent form of musculoskeletal pain that impedes everyday activities and reduces productivity.those who experience difficulties with regional pain frequently report myofascial pain. according to statistics, between 85% and 93% of patients who attend specialized pain treatment facilities and between 21% and 30% of people with regional pain who visit a general medical clinic also have it.trigger points, which are hyperirritable tender spots in palpably tense bands of skeletal muscles, are what define it. these spots can cause referred pain patterns, painfully limited range of motion, stiffness, muscle fatigue, and autonomic dysfunction. numerous clinical therapies as well as training regimens have been developed to combat trigger points. strain counterstrain technique (scs), is one of several manual methods for trigger points, which is a passive method that opens shortened tissues and reduces musculoskeletal pain. it may be possible to activate the golgi tendon organ, which relaxes tense and tight muscles, by positioning shortened and painful tissues in a comfortable way, which would result in a reduction in the sensitivity of the trigger point. hence, the purpose of this study is to ascertain how scs affects pain, rom, and functional disability in individuals suffering from lower back myofascial pain syndrome.

Eligibility criteria:
inclusion criteria: 1. the patients age from 20 to 40 years for both genders. 2. patients (office worker) with mechanical back pain for 3 months ago and has not been diagnose as a specific disease or spinal abnormality. 3. patients suffering from active mtrps in lower back muscle. 4. according to the oswestry low back pain disability questionnaire, patients suffered moderate disability care (20-40%). 5. patients capable of doing rom assessment of lumbar spine (flexion, extension, as well as side binding) within the limit of pain. exclusion criteria: 1. neurological, systemic illness and infectious diseases such as rheumatologic diseases, tumor. 2. psychiatric/mental deficit. 3. patients who had a previous surgical history (within 6 months) were also excluded prior to the baseline assessment. 4. vertebral compression fracture 5. pregnancy and lactation. 6. existing lower limb symptoms. 7. activity intolerance due to cardiopulmonary disease.

Keywords: low back pain myofascial pain syndrome strain counter strain technique trigger point
aerobe cycling training in women with unexplained recurrent pregnancy loss

Conditions: Recurrent Pregnancy Loss

Summary: in 50% of women with recurrent pregnancy loss (rpl) miscarriages are unexplained, therefore no therapeutic intervention is possible. in a pilot study, women with unexplained rpl showed less endometrial nk cells (enk) compared to women with a previously uncomplicated pregnancy. it is known that enk cells are important for embryo implantation during early pregnancy. investigators presume that high sympathetic activity in these women is related to enk cell number, function and phenotype and that exercise is an effective intervention to lower sympathetic activity and to influence the immune system, as especially peripheral nk cells have been assumed to be responsive to physical training. the investigators hypothesize that moderate exercise can lower the adrenergic tone of the sympathetic nervous system hereby influencing endometrial nk cells in women with rpl and eventually pregnancy outcome.


Eligibility criteria:
inclusion criteria: * rpl defined as 2 or more unexplained pregnancy losses from the time of conception until 24 weeks of gestation, known cause for the miscarriages are the presence of thyroid abnormalities, anti-phospholipid syndrome, uterine malformation, and abnormal parental karyotype according to international guideline. * couples should not be aiming to conceive during the time course of the exercise intervention. exclusion criteria: * age above 40 years * bmi above 40 * current use of immunosuppressive or biological drugs * current use of hormone conceptive * hiv positivity * current or recent (\<2 weeks) symptomatic genital infection such as chlamydia, gonorroa, or pelvic inflammatory disease * pre-existent diabetes mellitus, autoimmune disease or overt cardiovascular disease * vaccination (i.e covid) within 1 month prior to or during sampling and intervention * new pregnancy at time of measurements, breastfeeding * current or recent (\<2-3 months ago) pregnancy * (physical) inabilities to follow moderate aerobe cycling training * participants who are not capable of signing the informed consent

Keywords: natural killer cells
pharmacokinetics of two different high-dose regimens of intravenous vitamin c in critically ill patients

Conditions: Multiple Organ Failure; Sepsis; Systemic Inflammatory Response Syndrome; Trauma

Summary: the purpose of this study is to determine the pharmacokinetic properties of two different dosage regimens of intravenous vitamin c in patients admitted to the intensive care unit with life-threatening illness.

rationale: critically ill patients with trauma or sepsis exhibit a high degree of vitamin c deficiency at icu admission and vitamin c plasma concentrations decrease even more during the first three days of admission. vitamin c is a natural anti-oxidant and crucial for endothelial and organ protection objective: to determine the pharmacokinetics of two high dose regimens of intravenous vitamin c in critically ill patients, in particular the attained plasma concentration and the fraction retained in the body and excreted in urine. study design: prospective randomized controlled pharmacokinetic intervention study study population: adult critically ill patients admitted to the icu of the vu university medical center, amsterdam, with sepsis or sirs after major surgery or trauma with a non-neurological sequential organ failure (sofa) score \>6 and an expected length of icu stay of \>96 hours. intervention (if applicable): patients will receive either 2 or 10 gram/day vitamin c intravenously twice daily for two days in bolus or continuous infusion.

Eligibility criteria:
inclusion criteria: * sepsis or systemic inflammatory response syndrome (sirs) after major surgery or trauma; * non-neurological sequential organ failure assessment (sofa) score \>6; * expected length of icu stay \> 96 hours; * written proxy consent by legal representative. exclusion criteria: * admission after out of hospital cardiac arrest * prior use of supplemental vitamin c in the week before * major bleeding * pre-existent renal insufficiency defined as an egfr of \< 30 ml/min/1.73 m2 (stadium 4-5) * expected need for renal replacement therapy within 48 hours * known glucose 6-phosphate dehydrogenase deficiency * history of urolithiasis or oxalate nephropathy * previous use of prolonged high dose vitamin c supplements * hemochromatosis

Keywords: critical care
observational study to evaluate safety and efficacy of insulin therapy in type 2 diabetes mellitus subjects failing on oral anti-diabetic agents

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in asia. the aim of this observational study is to evaluate the incidence of major hypoglycaemic episodes and other adverse events, and to evaluate efficacy while using insulin under normal clinical practice conditions. the switch from oad treatment to insulin therapy will be determined by physician.


Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least 12 months and currently receiving oral anti-diabetic (oad) treatment, whether single or combination, for at least 3 months before this study * insulin naive * poor glycaemic control on oads and decided by the physician to start insulin therapy exclusion criteria: * type 1 diabetes patients * patients who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit * patients with a hypersensitivity to insulin or to any of the excipients * patient groups not approved in the product label
next-generation synbiotic in individuals with overweight or obesity

Conditions: Overweight and Obesity

Summary: this study plans to evaluate the effect of consuming a symbiotic (probiotic + prebiotic) for 3 months on body weight, body composition, glucose sensitivity, and psychological parameters, as well as on gut and blood microbial composition. synbiotic consumption is preceded by a 3-day antibiotic course to help ensure the opening of new niches (houses) for the upcoming beneficial bacteria.

this is a triple-blinded, randomized clinical trial in which participants will be allocated to one of two groups: 1) 3-day antibiotic followed by synbiotic consumption for 3 months or 2) 3-day antibiotic followed by placebo consumption for 3 months. blood and stool samples will be collected before the antibiotic, and before and after the symbiotic intervention in both groups. gut microbial composition will be analyzed through whole genome sequencing and blood microbial composition through 16s rrna. glucose sensitivity will be measured through fasting glucose, fasting insulin, and hba1c. body composition through dxa and bodpod will be measured before and after the symbiotic intervention. psychological questionnaires such as the beck anxiety and the beck depression inventories, as well as the red-9 questionnaire to respectively measure anxiety, depression, and food cravings, will be applied before and after the symbiotic intervention.

Eligibility criteria:
inclusion criteria: * be between 18-50 years of age * have a bmi between 25.0-40.0 exclusion criteria: * are following a vegetarian, vegan, carnivore, or keto diet * currently taking metformin, glp-1 agonists, insulin, or fiber * have taken antiacids, laxatives, probiotics, or medication that affects your immune system in the past month * pregnant, planning pregnancy during the study period, or lactating * have a history of inflammatory bowel disease, colon cancer, or chronic polyps * have been diagnosed with type 1 or type 2 diabetes * have active cancer * are currently participating in a weight loss intervention (dietetic or medication) * have used antibiotics, antifungals, or antivirals in the past 3 months * have had a history of recent (within 30 days) diarrhea illness * have a known allergy to any component of the study product * have had an acute inflammatory infection or inflammatory condition in the past 4 weeks * have had \>10% weight variation in the past 6 months * have had any bariatric surgery
a bundled rapid hiv/hcv testing intervention to increase receipt of test results

Conditions: Substance-related Disorders

Summary: this is a randomized controlled clinical trial in which adults receiving drug abuse treatment will be recruited to participate in a hiv and hepatitis c (hcv) testing study. the purpose of this study is to test the efficacy of two hiv/hcv testing strategies on increasing receipt of test results: (1) on-site bundled rapid hiv/hcv testing (i.e., joint offer of hiv and hcv at the point of encounter), and (2) standard of care for hiv and hcv testing.

this is a randomized controlled clinical trial in which adults receiving drug abuse treatment will be recruited to participate in a hiv and hepatitis c (hcv) testing study. the purpose of this study is to test the efficacy of two hiv/hcv testing strategies on increasing receipt of test results: (1) on-site bundled rapid hiv/hcv testing (i.e., joint offer of hiv and hcv at the point of encounter), and (2) standard of care for hiv and hcv testing. secondary outcomes include linkage to care and hiv and hcv risk behaviors. participants will complete a baseline assessment to report their demographics, sexual risk behaviors, drug-using risk behaviors, utilization of drug abuse treatment services and will be randomized to one of two groups. at one-month post-randomization, participants will complete a follow-up assessment to determine whether or not they received their hiv or hcv test results. at three months post-randomization, participants will complete a follow-up assessment to assess linkage to care and changes, if any, in their hiv and hcv sexual risk behaviors.

Eligibility criteria:
inclusion criteria: * report being hiv and hcv negative, or report not knowing hiv and hcv status * not have received results of an hiv or hcv test initiated within the last 12 months * able and willing to provide informed consent * seeking or currently receiving drug (excluding alcohol only treatment) abuse treatment services at the participating treatment programs * at least 18 years old * able to communicate in english * willing to sign a release form that will allow medical record review (to corroborate self-reports of receipt of test results) * able and willing to provide locator information (contact number and address) for follow-up surveys

Keywords: hiv hcv
evolution of the pr interval in patients implanted with a pacemaker using the safer mode

Conditions: Sinus Node Dysfunction; Atrioventricular Block

Summary: observational study on long pr interval using the safer mode in bradycardia patients.

this observational trial aims to study the evolution of the pr interval in patients implanted with a dual chamber pacemaker with the safer mode. the investigators will assess the prevalence and the incidence of pr lengthening and the investigators will study the long pr interval management by physicians, depending on the data embedded in the pacemaker.

Eligibility criteria:
inclusion criteria: * patient implanted (primo-implant, replacement, upgrade) with a sorin group™ dual chamber pacemaker according to current available guidelines and ifu from less than three months. * since implantation, the device is programmed in safer mode * patient agreed to participate, after having received the appropriate and mandatory information exclusion criteria: * patient contraindicated for cardiac pacing, according to current available guidelines * permanent atrial fibrillation * permanent high-degree av block * patient not available for routine follow-up visits * patient already included in another clinical study * inability to understand the purpose of the study / refusal to cooperate * minor age * pregnancy * life expectancy less than 12 months * under guardianship

Keywords: bradycardia